Lenzilumab inhibits the macrophage and monocyte activating cytokine Granulocyte–macrophage colony-stimulating factor (GM-CSF) in preclinical trials, which results in a reduction in neurotoxicity and CRS and an increase in CAR T-cell activation [151, 152]. The gene discussed is CSF2; the disease is congenital rubella syndrome.